Literature DB >> 18230779

Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease.

J Michael Collaco1, Lori Vanscoy, Lindsay Bremer, Kathryn McDougal, Scott M Blackman, Amanda Bowers, Kathleen Naughton, Jacky Jennings, Jonathan Ellen, Garry R Cutting.   

Abstract

CONTEXT: Disease variation can be substantial even in conditions with a single gene etiology such as cystic fibrosis (CF). Simultaneously studying the effects of genes and environment may provide insight into the causes of variation.
OBJECTIVE: To determine whether secondhand smoke exposure is associated with lung function and other outcomes in individuals with CF, whether socioeconomic status affects the relationship between secondhand smoke exposure and lung disease severity, and whether specific gene-environment interactions influence the effect of secondhand smoke exposure on lung function. DESIGN, SETTING, AND PARTICIPANTS: Retrospective assessment of lung function, stratified by environmental and genetic factors. Data were collected by the US Cystic Fibrosis Twin and Sibling Study with missing data supplemented by the Cystic Fibrosis Foundation Data Registry. All participants were diagnosed with CF, were recruited between October 2000 and October 2006, and were primarily from the United States. MAIN OUTCOME MEASURES: Disease-specific cross-sectional and longitudinal measures of lung function.
RESULTS: Of 812 participants with data on secondhand smoke in the home, 188 (23.2%) were exposed. Of 780 participants with data on active maternal smoking during gestation, 129 (16.5%) were exposed. Secondhand smoke exposure in the home was associated with significantly lower cross-sectional (9.8 percentile point decrease; P < .001) and longitudinal lung function (6.1 percentile point decrease; P = .007) compared with those not exposed. Regression analysis demonstrated that socioeconomic status did not confound the adverse effect of secondhand smoke exposure on lung function. Interaction between gene variants and secondhand smoke exposure resulted in significant percentile point decreases in lung function, namely in CFTR non-DeltaF508 homozygotes (12.8 percentile point decrease; P = .001), TGFbeta1-509 TT homozygotes (22.7 percentile point decrease; P = .006), and TGFbeta1 codon 10 CC homozygotes (20.3 percentile point decrease; P = .005).
CONCLUSIONS: Any exposure to secondhand smoke adversely affects both cross-sectional and longitudinal measures of lung function in individuals with CF. Variations in the gene that causes CF (CFTR) and a CF-modifier gene (TGFbeta1) amplify the negative effects of secondhand smoke exposure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18230779      PMCID: PMC3139475          DOI: 10.1001/jama.299.4.417

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  37 in total

1.  Passive smoking in cystic fibrosis.

Authors:  H Gilljam; C Stenlund; A Ericsson-Hollsing; B Strandvik
Journal:  Respir Med       Date:  1990-07       Impact factor: 3.415

2.  Association of poor clinical status and heavy exposure to tobacco smoke in patients with cystic fibrosis who are homozygous for the F508 deletion.

Authors:  P W Campbell; R A Parker; B T Roberts; M R Krishnamani; J A Phillips
Journal:  J Pediatr       Date:  1992-02       Impact factor: 4.406

Review 3.  The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel.

Authors:  B J Rosenstein; G R Cutting
Journal:  J Pediatr       Date:  1998-04       Impact factor: 4.406

Review 4.  Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis.

Authors:  M J Welsh; A E Smith
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

5.  Relationship between socioeconomic status and disease severity in cystic fibrosis.

Authors:  M S Schechter; P A Margolis
Journal:  J Pediatr       Date:  1998-02       Impact factor: 4.406

6.  Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis.

Authors:  M Corey; L Edwards; H Levison; M Knowles
Journal:  J Pediatr       Date:  1997-12       Impact factor: 4.406

7.  Passive smoking and lung function in cystic fibrosis.

Authors:  T Kovesi; M Corey; H Levison
Journal:  Am Rev Respir Dis       Date:  1993-11

8.  Passive smoking and impaired lung function in cystic fibrosis.

Authors:  A Smyth; U O'Hea; G Williams; R Smyth; D Heaf
Journal:  Arch Dis Child       Date:  1994-10       Impact factor: 3.791

9.  Transforming growth factor-beta1 genotype and susceptibility to chronic obstructive pulmonary disease.

Authors:  L Wu; J Chau; R P Young; V Pokorny; G D Mills; R Hopkins; L McLean; P N Black
Journal:  Thorax       Date:  2004-02       Impact factor: 9.139

10.  The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD).

Authors:  Juan C Celedón; Christoph Lange; Benjamin A Raby; Augusto A Litonjua; Lyle J Palmer; Dawn L DeMeo; John J Reilly; David J Kwiatkowski; Harold A Chapman; Nan Laird; Jody S Sylvia; Melvin Hernandez; Frank E Speizer; Scott T Weiss; Edwin K Silverman
Journal:  Hum Mol Genet       Date:  2004-06-02       Impact factor: 6.150

View more
  60 in total

Review 1.  Cystic fibrosis papers of the year 2010-2011.

Authors:  David Honeybourne
Journal:  J R Soc Med       Date:  2012-06       Impact factor: 5.344

2.  Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function.

Authors:  J Michael Collaco; Scott M Blackman; John McGready; Kathleen M Naughton; Garry R Cutting
Journal:  J Pediatr       Date:  2010-06-30       Impact factor: 4.406

3.  Smoking prevention and cessation programme in cystic fibrosis: integrating an environmental health approach.

Authors:  Juan Antonio Ortega-García; María Trinidad López-Fernández; Rayden Llano; María Dolores Pastor-Vivero; Pedro Mondéjar-López; Miguel Felipe Sánchez-Sauco; Manuel Sánchez-Solís
Journal:  J Cyst Fibros       Date:  2011-10-13       Impact factor: 5.482

4.  The genetics and genomics of cystic fibrosis.

Authors:  N Sharma; G R Cutting
Journal:  J Cyst Fibros       Date:  2019-12-23       Impact factor: 5.482

5.  Cat and dog exposure and respiratory morbidities in cystic fibrosis.

Authors:  Christopher B Morrow; Karen S Raraigh; Deanna M Green; Scott M Blackman; Garry R Cutting; Joseph M Collaco
Journal:  J Pediatr       Date:  2014-07-12       Impact factor: 4.406

6.  Socioeconomic Status, Smoke Exposure, and Health Outcomes in Young Children With Cystic Fibrosis.

Authors:  Thida Ong; Michael Schechter; Jing Yang; Limin Peng; Julia Emerson; Ronald L Gibson; Wayne Morgan; Margaret Rosenfeld
Journal:  Pediatrics       Date:  2017-01-16       Impact factor: 7.124

Review 7.  Update on gene modifiers in cystic fibrosis.

Authors:  Joseph M Collaco; Garry R Cutting
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

8.  Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis.

Authors:  Michael S Schechter; Susanna A McColley; Stefanie Silva; Tmirah Haselkorn; Michael W Konstan; Jeffrey S Wagener
Journal:  J Pediatr       Date:  2009-07-16       Impact factor: 4.406

9.  Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis.

Authors:  Don B Sanders; Julia Emerson; Clement L Ren; Michael S Schechter; Ronald L Gibson; Wayne Morgan; Margaret Rosenfeld
Journal:  Ann Am Thorac Soc       Date:  2015-08

10.  The effect of titanium dioxide nanoparticles on pulmonary surfactant function and ultrastructure.

Authors:  Carsten Schleh; Christian Mühlfeld; Karin Pulskamp; Andreas Schmiedl; Matthias Nassimi; Hans D Lauenstein; Armin Braun; Norbert Krug; Veit J Erpenbeck; Jens M Hohlfeld
Journal:  Respir Res       Date:  2009-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.